The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.
Dharminder Chauhan
Consultant or Advisory Role - Triphase Accelerator Corp
Deepika Sharma Das
No relevant relationships to disclose
Arghya Ray
No relevant relationships to disclose
Paul G. Richardson
No relevant relationships to disclose
Mohit Trikha
Employment or Leadership Position - Triphase Accelerator Corp
Stock Ownership - Triphase Accelerator Corp
Kenneth Carl Anderson
No relevant relationships to disclose